+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 30Years - 80Years
All Genders
ID07518810

Evaluation of Butylphthalide Capsules for Treating Symptoms of Multiple System Atrophy A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Led by Second Affiliated Hospital, Zhejiang University, School of Medicine · Updated on 2026-10-16

150

Participants Needed

7

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a randomized controlled trial to assess the effectiveness and safety of 3-n-Butylphthalide NBP in improving symptoms of Multiple System Atrophy MSA. This study aims to determine if NBP soft capsules can alleviate major clinical symptoms compared to a placebo and to evaluate the safety of NBP in treating MSA patients. Participants will be randomly assigned to receive either NBP soft capsules or placebo capsules. Those in the NBP group will take two 100 mg capsules three times daily, totaling 600 mg per day, for six months while maintaining their existing medications. The placebo group will take capsules identical in appearance but without active ingredients, also three times daily for six months. During the study, participants will have four clinical visits for follow-up and tests and will keep a diary to record medication use and symptom changes. Researchers will measure main symptom control at baseline and at 1, 3, 6, and 12 months after starting treatment, along with secondary assessments including overall symptoms, autonomic function, mood, cognitive function, quality of life, and safety over approximately one year.

CONDITIONS

Brief Title

Efficacy and Safety of Butylphthalide in the Treatment of Multiple System Atrophy

Research Team

J

Jiali Pu, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here